Next-generation drug development: risky and costly, but worth it

	Tweet

Generic drugs, which drive a $40 billion dollar generics industry expected to hit $60 billion by 2007, account for 53% of all prescriptions filled in the United States today.

According to a new report from pharmaceutical research firm Cutting Edge Information, brand name companies have turned to the risky business of next- generation drug development to protect revenues from generic competitors.

“Next-generation drug development is chancy because substantial investment must be made up-front and without a guarantee of return,” said Eric Bolesh, lead author of “Combating Generics: Pharmaceutical Brand Defense for 2007”. “However, next-generation development is one of the most effective means of protecting revenue streams from off-brand challengers.”

Next-generation development has had its successes and failures. The industry’s ideal is AstraZeneca’s Prilosec-to-Nexium switch. Before generic competitors hit the heartburn market, AstraZeneca had successfully switched 40% of its Prilosec customers to Nexium. By Prilosec’s 2nd year of generic exposure, AstraZeneca managed to grow its franchise by almost 9%.

GlaxoSmithKline’s Augmentin did not fare as well. Franchise sales plummeted 72% in the US - despite the launch of Augmentin XR, an extended release form - when Augmentin first faced its generic competitors in 2002.

Cutting Edge Information’s study, “Combating Generics: Pharmaceutical Brand Defense for 2007”, examines numerous strategies to counter generic drugs. The report, which contains illustrative case studies, explores a number of strategies in detail and identifies critical principles for success.

“Setting realistic goals and having a well-thought-out plan is important. Generic competition in any given market is inevitable. Start your next- generation drug development early—just after product launch—and be ready to show patients that the benefits gained from the scientific advances of a next-generation drug outweigh the savings that come from switching to generics,” said Bolesh.

http://www.pharmagenerics.com/

RELATED STORIES:
Lilly stops pediatric trial of sepsis drug   US approves treatment for smallpox shot reaction   U.S. FDA looking to improve drug safety monitoring   Diet-pill seller agrees $155 mln fraud settlement   Viagra helps childhood lung condition   Advair may improve COPD survival: clinical trial   Expert Warns of Overuse of Over-the-Counter Pain Medication   New anthrax vaccine promises rapid protection   Tests compare drugs for hepatitis   Drug reduces work productivity lost to migraines   “Miracle” Cancer Drug Gleevec Can be Toxic to the Heart   Long-term use of popular inhalers increases risk of pneumonia for COPD patients

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]